Topoisomerase II inhibitor-related acute myeloid leukaemia

Br J Haematol. 2000 Apr;109(1):13-23. doi: 10.1046/j.1365-2141.2000.01843.x.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Chromosomes, Human, Pair 11
  • DNA-Binding Proteins / genetics
  • Disease Susceptibility
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Synergism
  • Gene Rearrangement / genetics
  • Histone-Lysine N-Methyltransferase
  • Humans
  • Leukemia, Myeloid / chemically induced*
  • Leukemia, Myeloid / genetics
  • Leukemia, Myeloid / therapy
  • Myeloid-Lymphoid Leukemia Protein
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Proto-Oncogenes*
  • Remission Induction
  • Risk Factors
  • Topoisomerase II Inhibitors*
  • Transcription Factors*
  • Translocation, Genetic / genetics

Substances

  • Antineoplastic Agents
  • DNA-Binding Proteins
  • KMT2A protein, human
  • Topoisomerase II Inhibitors
  • Transcription Factors
  • Myeloid-Lymphoid Leukemia Protein
  • Histone-Lysine N-Methyltransferase